Curated news and analysis on clinical trials, drug approvals, and medical research.
DX-104, a next-generation gOMV vaccine candidate for MenB, is planned for trials in China and Australia. The process scaled to 100 L, reached 98% purity, and is projected to yield over 1 million doses per batch.
Sino Biopharmaceutical won Chinese approval for a new indication for benmelstobart as maintenance therapy in unresectable stage III NSCLC after chemoradiotherapy. Phase III R-ALPS data showed significantly prolonged progression-free survival versus placebo and a manageable safety profile.
Two studies reported mitochondrial mechanisms linked to diabetic wound repair, including targeted mitochondrial transplantation and the circular RNA circMTRNR2. The findings showed improved healing in experimental models and identified potential targets for chronic wound treatment.
Tracy Beth Høeg said in her first address to staff that she will scrutinize antidepressants and RSV products used to protect babies. She said she is prioritizing the health of women and babies.
Insulin list prices rose more than 300% over two decades as PBMs face growing scrutiny over rebates, spread pricing, and transparency. Reform efforts and pharmacist involvement are central to drug affordability and access.
Thrive Capital has raised more than $10 billion in its largest fund ever. The fundraising was heavily oversubscribed and the cash influx was double the size of its last fund.
Police in Karachi, Kentucky and Indiana arrested three suspects in separate drug investigations involving alleged trafficking in Ice, methamphetamine and cocaine. One case involved a controlled purchase, while another led to the seizure of nearly 60 grams of cocaine and a firearm.
A mouse study identified **TRPV4** as part of the neural feedback system that tells the brain when scratching has been sufficient. The findings suggest broadly blocking TRPV4 may not be the solution for chronic itch.
The FDA expanded efgartigimod approval to all adult generalized myasthenia gravis serotypes. Phase 3 ADAPT SERON met its primary endpoint and showed no new safety signals.
Research found variation in guideline-concordant colorectal cancer care across hospitals and systems, while a separate study highlighted the role of specialized cancer nurses in reducing distress and improving support.
The Department of Biotechnology has opened recruitment for 10 Scientist ‘C’ posts in Pay Matrix Level-11. Applications open February 14, 2026 and close March 15, 2026.
Dinoflagellates were shown to accumulate nitrogen heterocycles from aqueous solutions into nitrogen-storage crystals and use them for growth. The crystallization behavior was manipulated to produce molecular crystals with tailored morphologies and optical properties.
Vertex secured a Germany reimbursement agreement for CASGEVY and signed a WuXi Biologics pact for a preclinical autoimmune T-cell engager. The moves add to efforts to build revenue beyond cystic fibrosis.
SoSoThin.com launched a cash-pay semaglutide weight loss service on February 16, 2026. The company said the model offers fast access, transparent pricing, and a digital-first process without insurance delays.
The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
PSMA-PET imaging leads to earlier use of advanced therapies like ARPIs in prostate cancer patients compared to bone scans. Real-world data on 177Lu-PSMA-617 shows comparable efficacy to the VISION trial in mCRPC patients.
Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.
Slow up-dosing peanut OIT enabled 82% of toddlers to tolerate 3.5 peanuts after treatment. Low-dose OIT was safe in preschoolers with single or multiple food allergies. Allergist guidance on anxiety was linked to reduced caregiver worry.
Merck's Enflonsia (clesrovimab) receives EU approval for RSV prevention in infants. Separately, researchers identify a monoclonal antibody cocktail from pediatricians' immune cells that shows potent protection against RSV and hMPV in animal studies.
